Showing results (201-210 of 2,508) with videos related to

Sort By:
Pageof 251
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell TransplantationAsmita Mishra, Claudio Anasetti
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Trends in Clinical Investigation for Myelodysplastic SyndromesThomas Prebet, Amer Zeidan
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome-Positive Chronic Myeloid LeukemiaJorge Luis Ángeles-Velázquez, Rafael Hurtado-Monroy, Pablo Vargas-Viveros, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 12, 2020
Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional StudyWellington F da Silva, Ires H B Massaut, Rodrigo M Bendlin, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 14, 2015
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaMuthu Veeraputhiran, Tania Jain, Abhinav Deol, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 28, 2020
Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal ChemotherapyJosep-Maria Ribera, Olga García, Eduardo Cerello Chapchap, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 14, 2020
RETRACTED: Drug-Induced ThrombocytopeniaMaroun Sadek, Georges El Hachem, Marie Vercruyssen
Clinical Lymphoma, Myeloma & Leukemia|April 13, 2020
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III StudiesMichele Cavo, Meletios A Dimopoulos, Jesus San-Miguel, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 4, 2020
Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma PatientsAbdullah S Al Saleh, Harsh V Parmar, Alissa Visram, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 28, 2020
KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell TransplantationAndrew J Cowan, Damian J Green, Mehdi Karami, et al.
Pageof 251